Alaunos Therapeutics(TCRT) - 2022 Q2 - Earnings Call Transcript

Financial Data and Key Metrics Changes - For Q2 2022, Alaunos reported a net loss of approximately $9.9 million or $0.05 net loss per share, compared to a net loss of approximately $22.7 million or $0.11 net loss per share for Q2 2021, indicating a significant improvement in financial performance [22] - Research and Development expenses decreased to approximately $5.9 million in Q2 2022 from approximately $13.6 million in Q2 2021, a reduction of 56% [22] - General and Administrative expenses were approximately $3.4 million for Q2 2022, down from approximately $9.1 million in the same period in 2021, a decrease of 62% [24] - Operating cash burn for Q2 2022 was $8.2 million, compared to $21.5 million in Q2 2021, a decrease of $13.3 million or 62% [25] Business Line Data and Key Metrics Changes - The TCR-T Library Phase 1/2 trial is actively enrolling patients, with the company moving to the second dose level after safety reviews [10] - The TCR-T library consists of 10 TCRs targeting hotspot mutations across six solid tumor indications, including non-small cell lung, colorectal, endometrium, pancreas, ovary, and bile duct cancers [10][11] Market Data and Key Metrics Changes - Over 500 lung and colorectal patients have been screened, with a match rate of over 5% for the TCRs in the library [40] - The company anticipates that the addition of new TCRs will increase the addressable market for its library TCR-T program [21] Company Strategy and Development Direction - The company is focused on expanding manufacturing capacity to support future clinical expansion and has implemented new SOPs for simultaneous production of multiple products [13] - Alaunos has extended its collaboration agreement with the National Cancer Institute (NCI) to 2025, aiming to develop personalized cancer therapies using its TCR-T cell platform [10][18] - The company is also advancing its membrane-bound IL-15 program towards an IND filing in the second half of 2023 [20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the progress of the TCR-T Library trial and the potential of their proprietary Sleeping Beauty technology for commercial scalability [12][19] - The company remains focused on improving the lives of cancer patients with solid tumors and is optimistic about the upcoming data presentation at a scientific conference [31] Other Important Information - Alaunos had approximately $60 million in cash and cash equivalents as of June 30, 2022, with a cash runway anticipated to fund operations into Q2 2023 [25] - The company is not expecting significant capital from royalties on sales from its collaboration with Solasia Pharma, which has been approved for a product in Japan [15][62] Q&A Session Summary Question: Has the second patient been dosed or identified? - Management indicated that they are excited about the trial's progress and will provide updates on patient dosing in the upcoming weeks [34][35] Question: What is the total number of patients screened and the match rate? - Over 500 patients have been screened, with a match rate exceeding 5%, which is encouraging for ongoing enrollment [40] Question: What types of patients are being screened? - Patients of all stages are being screened, including those newly diagnosed and those who may have failed frontline therapies [42] Question: Is manufacturing capacity a limiting factor for patient treatment? - Currently, manufacturing is not a limiting factor, and the company is working on optimizing processes to increase throughput [46] Question: What are the anticipated total patients to be dosed for the Phase 1/2 study? - The company plans to let the science guide the number of patients treated, emphasizing a flexible trial design [53] Question: What is the expected timeline for commercialization with Solasia? - The company expects low single-digit royalties from Solasia, which will not significantly alleviate capital needs but will support R&D efforts [62]